Login
RIGEL PHARMACEUTICALS INC logo

RIGEL PHARMACEUTICALS INC

rigel.com

What Do They Do?

Sells prescription medicines for patients with blood disorders and cancers, including TAVALISSE, REZLIDHIA and GAVRETO.

How Do They Make Money?

Customers pay for medicines when specialty distributors receive delivery. Collaboration partners pay for license rights, milestones, drug supplies and royalties on licensed-product sales.

revenue
SegmentShareRevenue
Total product sales, net
Sold outright

79%
FY2022: 64%
Total revenues from collaborations
21%
FY2022: 32%
Government contracts
0.1%
FY2022: 3.7%

Who Are Their Customers?

U.S. product sales go to specialty distributors, which resell to specialty pharmacies, health care providers, hospitals and clinics. Collaboration partners license rights, buy drug supplies and pay royalties or milestones.

Customers above 10% of revenue, FY2025
of revenue from three customers (42%, 19%, 14%)
FY2023: 89% from three customers

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue.

Operating income, FY2025
43% of revenue
▲ +419% vs FY2024 ($24.2M, 13%)
Net income, FY2025
125% of revenue
▲ +1999% vs FY2024 ($17.5M, 10%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +16%
vs $69.5M in Q3 FY2025
Net income
▼ −53%
vs $27.9M in Q3 FY2025
Product sales, net share of revenue vs 92.2% in Q3 FY2025
  • Aug 4, 2026 In-licensed VEPPANU and updated the revenue outlook Rigel expects 2026 total revenues of approximately $285 to $295 million.
  • Apr 21, 2026 Lilly terminated its collaboration agreement Rigel expects no future milestones or royalties under the agreement.

Growing. Revenue grew 97% in 4 years, from $149.2M in FY2021 to $294.3M in FY2025, about 19% a year.

Added GAVRETO to marketed medicines The latest report describes GAVRETO as a marketed medicine for lung and thyroid cancers; the older report describes TAVALISSE and REZLIDHIA as its commercial products.

Revenue over time
Total product sales, net Total revenues from collaborations Government contracts Release Of Share Cost Liability
$500M$250M$0

Who Do They Compete With?

Competes with Sanofi, Novartis International, Amgen, Dova Pharmaceuticals, and Teva Pharmaceutical Industries

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support